Ipilimumab/nivolumabImmune-mediated colitis : case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1885卷 / 1期

关键词：

D O I：

10.1007/s40278-021-07040-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：281 / 281

相关论文

共 50 条

[1] Ipilimumab/nivolumabImmune-mediated colitis: case report
Reactions Weekly, 2021, 1836 (1) : 437 - 437
[2] Ipilimumab/nivolumabImmune-mediated colitis: case report
Reactions Weekly, 2021, 1836 (1) : 436 - 436
[3] Ipilimumab/nivolumabImmune-mediated colitis: case report
Reactions Weekly, 2018, 1729 (1) : 151 - 151
[4] Ipilimumab/nivolumabImmune-mediated colitis: case report
Reactions Weekly, 2024, 2022 (1) : 155 - 155
[5] NivolumabImmune-mediated colitis: case report
Reactions Weekly, 2025, 2041 (1) : 308 - 308
[6] Ipilimumab/nivolumabImmune-mediated colitis and immune-mediated dermatitis: case report
Reactions Weekly, 2021, 1836 (1) : 435 - 435
[7] Ipilimumab/methylprednisolone/nivolumabImmune-mediated colitis and lack of efficacy: case report
Reactions Weekly, 2022, 1927 (1) : 304 - 304
[8] Ipilimumab/nivolumabImmune-mediated thyroiditis: case report
Reactions Weekly, 2023, 1957 (1) : 311 - 311
[9] Ipilimumab/nivolumabImmune-mediated meningoencephalitis: case report
Reactions Weekly, 2022, 1895 (1) : 231 - 231
[10] NivolumabImmune-mediated colitis: case report
Reactions Weekly, 2020, 1793 (1) : 342 - 342

← 1 2 3 4 5 →